The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a multicenter longitudinal study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD) in order to improve the design of clinical trials of Alzheimer therapeutics. The study recruits participants from 60 sites throughout North America, and these individuals undergo PET imaging (for Aβ, tau and glucose metabolism), MRI, blood testing, cognitive testing, and genetic testing. The PET Core is centered in Berkeley and includes Dr. Jagust (lead), Dr. Koeppe (University of Michigan), and Dr. Landau, and is responsible for quality control, processing, and quantitative analysis of amyloid, FDG, and tau PET data. This data is uploaded to the ADNI database at the Laboratory of Neuroimaging (University of Southern California) and is made available for all participating researchers to access. A key feature of ADNI is its open data sharing policy, allowing qualified researchers from around the globe full access to ADNI data.
More information can be found at ADNI’s homepage.